Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
ID: RFA-DA-25-054Type: BOTH
Overview

Topic

Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2024

Topic Link

https://www.sbir.gov/node/2504573

Additional Information

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-054.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)". This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy for the prevention or treatment of substance use disorders (SUDs). The traditional drug discovery paradigm of single-target-based approaches has limitations in addressing the complex mechanisms and polysubstance use associated with SUDs. Polypharmacology, the study of how drug molecules interact with multiple targets, is emerging as a new paradigm for drug development in multifactorial diseases like SUDs. The use of AI/ML technologies trained in polypharmacology can enhance the identification of SUD pharmacotherapeutics by evaluating and predicting the effects of binding to multiple biological targets, reducing toxicity, and informing in vitro and in vivo assays. The research objectives include identifying and validating disease targets, screening potential compounds, developing assays, synthesizing novel compounds, and conducting toxicity and efficacy studies. The Small Business Innovation Research (SBIR) program offers Phase I and Phase II funding opportunities to establish technical merit, feasibility, and commercial potential. Successful SBIR projects are expected to attract strategic partners or investors for ultimate commercialization. Phase I, Fast Track, and Direct to Phase II applications are accepted in response to this solicitation. The application due date is July 25, 2024. For more information, visit the solicitation agency website.

    Files
    No associated files provided.
    Similar Opportunities
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis surrounding OUD/StUD is a significant issue, with over 100,000 overdose deaths reported in a one-year period. The goal of this solicitation is to offer new medical products that can monitor, diagnose, and treat patients suffering from these disorders. The solicitation is open to small business companies that have developed or are developing FDA-regulated products for different indications and are interested in demonstrating their potential application in the OUD/StUD space. The research and development activities may fall into two areas: pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The proposed projects should aim to address the needs of patients suffering from OUD/StUD and may include activities such as target identification, lead optimization, preclinical studies, formulation development, and clinical trials. The funding for these projects will be provided through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding available. The application due dates are August 15, 2023, February 14, 2024, August 13, 2024, and February 14, 2025. For more information and to apply, interested parties can visit the grants.gov website or the solicitation agency URL provided.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulant use disorders (OUD/StUD). The current drug crisis surrounding these disorders has resulted in a significant number of deaths and an urgent need for comprehensive solutions. The solicitation is focused on the research and development of medical products regulated by the U.S. Food and Drug Administration (FDA), including pharmacotherapeutics and medical therapeutic and diagnostic devices. In the area of pharmacotherapeutics, the solicitation encourages the development of small or large molecule agents, biologics, natural products, longer-acting formulations of existing addiction medications, advanced drug delivery systems, and the development and characterization of biomarkers. Proposed activities may include target identification, assay development, lead optimization, preclinical studies, formulation development, and process development. The ultimate goal is to file an Investigational New Drug (IND) application and conduct clinical studies to support the filing of a New Drug Application (NDA) or a Biological License Application (BLA). In the area of medical therapeutic and diagnostic devices, the solicitation seeks research and development of imaging technologies, devices for diagnosing and reducing craving and withdrawal symptoms, therapeutic devices, devices for treating pediatric patients, in vitro diagnostic assays, digital therapeutics, devices for detecting and treating opioid-induced respiratory depression, and data science and cloud-based technologies. Proposed activities may include studies supporting an Investigational Device Exemption application, process development, non-clinical safety studies, clinical trials, and engagement with the FDA Center of Devices and Radiological Health. The goal is to successfully file an FDA premarket application for clearance/approval. The solicitation is open for applications and offers funding for Phase I, Phase II, and Fast Track projects. Phase I aims to establish the technical merit and feasibility of the proposed research, while Phase II continues the R&D efforts to advance the technology toward commercialization. Fast Track applications combine Phase I and Phase II into one application to reduce or eliminate the funding gap between phases. Small businesses that have received Phase I STTR awards are eligible to submit Phase II applications as "Renewal" applications.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by Opioid and/or Stimulants use Disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus for this solicitation are pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The research topics may include the development of new medications, longer-acting formulations, advanced drug delivery systems, biomarkers, imaging technologies, therapeutic devices, in vitro diagnostic assays, and digital therapeutics. The projects proposed under this solicitation may fall under Phase I, Phase II, Fast Track, or Direct to Phase II categories. The funding opportunity is open until February 15, 2025. For more information and to apply, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Phase II applications, including Fast-Track applications. The application due date is March 13th of each year, starting in 2024. For more information, visit the solicitation link.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Phase II applications, including Fast-Track applications that combine both phases. The deadline for submission is March 14, 2026. For more information, visit the solicitation agency URL: link.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The goal is to fill the service gaps that government and the medical community cannot address alone. The technologies should focus on reducing costs, time, and/or increasing access in addressing housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide feasible and accessible opportunities for end-users to improve their health-related social needs and SUD outcomes. The solicitation is open for Phase I and Fast-Track (Phase I/Phase II) applications, with a focus on establishing technical feasibility and commercial potential. The application due date is March 13th, 2024, with subsequent due dates in 2025 and 2026. More information can be found on the grants.gov website.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder. The purpose of this funding opportunity is to support small business concerns in developing technologies for commercialization that can fill the service gaps in addressing SUD. The research objectives include developing products that reduce costs, time, and increase access in addressing health-related social needs such as housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The technologies can include physical devices, digital services, software, or non-physical/non-tangible products. The funding opportunity is open for applications until March 14, 2026, and offers both Phase I and Phase II funding options. Phase I focuses on establishing technical merit and feasibility, while Phase II aims to advance technologies towards commercialization. Applicants are encouraged to review the guidelines and adhere to the requirements applicable to their research.
    Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of medications to treat Alcohol Use Disorder (AUD) and Alcohol-Associated Organ Damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with strong background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. The research objectives include advancing small molecules, natural products, and biologics through pre-clinical development, IND-enabling toxicology, and clinical development phases. The program emphasizes the importance of adherence to compliance and quality criteria, including Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). Intellectual property development and retention is strongly encouraged, and applications that focus on animal model development, basic research, or activities already funded by other sources will not be considered. For more information and to apply, visit the solicitation agency URL: link.
    Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of medications to treat Alcohol Use Disorder (AUD) and Alcohol-Associated Organ Damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with strong background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The research objectives include pre-clinical development, IND-enabling toxicology, clinical development, and small early-phase clinical trials. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. For more information, visit the solicitation agency URL: link.
    Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the investigational new drug (IND)-enabling and early-stage development of medications to treat alcohol use disorder (AUD) and alcohol-associated organ damage (AAOD). Currently, there are only three FDA-approved medications for AUD, and there are no approved therapies for AAOD. The goal of this funding opportunity is to advance small molecules, natural products, or biologics for AUD and AAOD through the drug development pipeline towards FDA approval and commercialization. Projects should focus on lead compounds with robust background data in basic science and early discovery phases, and should aim to achieve milestones that move the compound towards the next phase of drug development. The research objectives include pre-clinical development, IND-enabling toxicology, clinical development, and small early-phase clinical trials. The funding period is open until December 5, 2024, and women-owned and socially or economically disadvantaged small businesses are encouraged to apply. For more information, visit the solicitation agency URL: link.